Targets › SSTR2
47 programs from 41 companies in 86 trials: 40 Phase 2, 23 Phase 1, 18 Phase 3, 5 Phase 4; Oncology, Gastroenterology, Metabolic and endocrine; next expected readout Nov 2026.
Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. (UniProt, P30874)
Open in Phaseline: the race on SSTR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Hospital, Antwerp | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 4 | Gastroenteropancreatic Neuroendocrine Tumor | Apr 2029 |
| Helsinki University Central Hospital | Pasireotide Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist | SSTR5, SSTR2, SSTR1, SSTR3 | Phase 4 | Pancreatic Fistula | Dec 2029 |
| Weill Medical College of Cornell University | Ga68-DOTATATE-PET/MRI Somatostatin receptor 2 (SSTR2) targeted PET/MRI imaging agent | SSTR2 | Phase 4 | CNS Tumors | Dec 2038 |
| Camurus | CAM2029 Somatostatin receptor agonist (octreotide subcutaneous depot) | SSTR2 | Phase 3 | Gastro-enteropancreatic Neuroendocrine Tumor; Polycystic Liver Disease | Nov 2026 |
| HTA | Lutetium Oxodotreotide Lu-177 Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | NETS Ga68 Lu177 | Nov 2026 |
| Jiangsu HengRui Medicine | Lutetium (177Lu) Oxodotreotide Injection Somatostatin receptor 2 (SSTR2)-targeting peptide radionuclide therapy | SSTR2 | Phase 3 | Advanced Gastroenteropancreatic Neuroendocrine Tumor | Dec 2026 |
| RayzeBio | RYZ101 Actinium-225 labeled somatostatin receptor agonist (SSTR-targeting radiopharmaceutical) | SSTR2 | Phase 3 | GEP-NET; SCLC,Extensive Stage; Metastatic Breast Cancer | Dec 2026 |
| ITM Solucin | 177Lu-edotreotide PRRT Peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors | SSTR2, SSTR5 | Phase 3 | Neuroendocrine Tumors | Jun 2027 |
| Crinetics Pharmaceuticals | Paltusotine Somatostatin receptor 2 agonist | SSTR2 | Phase 3 | Carcinoid Syndrome | Aug 2027 |
| Advanced Accelerator Applications | Lutetium Oxodotreotide Lu-177 Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | Gastro-enteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumors; Digestive System Neuroendocrine Tumor G1; Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) … | Oct 2027 |
| Debiopharm International | Debio 4126 somatostatin analog (somatostatin receptor agonist) | SSTR2, SSTR5 | Phase 3 | Acromegaly | Jun 2028 |
| Novartis | [177Lu]Lu-DOTA-TATE SSTR2-targeted radioligand therapy with lutetium-177 | SSTR2 | Phase 3 | Somatostatin Receptor Positive (SSTR+); Metastatic Neuroendocrine Prostate Cancer | Dec 2028 |
| Sinotau Pharmaceutical Group | Lutetium Oxodotreotide Lu-177 Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | Neuroendocrine Tumors | Dec 2028 |
| Grupo Espanol de Tumores Neuroendocrinos | 177Lu-edotreotide Somatostatin receptor 2 (SSTR2) agonist labeled with lutetium-177 for radionuclide therapy | SSTR2 | Phase 3 | Neuroendocrine Tumors | Mar 2029 |
| SWOG Cancer Research Network | Lanreotide Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist | SSTR5, SSTR2 | Phase 3 | Pancreatic Carcinoma | Apr 2029 |
| Washington University School of Medicine | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | Neuroendocrine Neoplasm | Nov 2034 |
| Lund University Hospital | 177Lu-DOTATOC somatostatin receptor 2 (SSTR2) targeting radiolabeled somatostatin analog | SSTR2 | Phase 3 | Neuroendocrine Tumors | – |
| HTA | 68Ga-DOTATATE Injection Somatostatin receptor 2 (SSTR2) agonist/imaging agent | SSTR2 | Phase 3 | NETs; Healthy (Controls); Metastic Thyroid Cancer; ACTH | – |
| University Hospital, Grenoble | 68Ga-DOTATOC Somatostatin receptor 2 (SSTR2) targeting PET imaging agent | SSTR2 | Phase 3 | Breast Cancer Metastatic | – |
| Tine Gregersen, MD | Lu-177-DOTATOC Somatostatin receptor 2 (SSTR2) targeting radiopharmaceutical; Lu-177 is a beta-emitting r | SSTR2 | Phase 2 | Neuroendocrine Neoplasm | Dec 2026 |
| The Netherlands Cancer Institute | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 2 | Neuroendocrine Tumors | Jan 2027 |
| Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 177Lu-DOTATOC Somatostatin receptor-targeted radionuclide therapy with lutetium-177 | SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 | Phase 2 | Neuroendocrine Tumors | Jan 2027 |
| Memorial Sloan Kettering Cancer Center | Pasireotide Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist | SSTR5, SSTR2, SSTR1, SSTR3 | Phase 2 | Prolactin-Producing Pituitary Tumor | Feb 2027 |
| Antonio Fojo | Lanreotide Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist | SSTR5, SSTR2 | Phase 2 | Paraganglioma | Mar 2027 |
| University Hospital, Bordeaux | LUTATHERA® by intra-arterial hepatic (IAH) injection Radiolabeled somatostatin analog (177Lu-DOTA-TATE) with intra-arterial hepatic delivery to | SSTR2 | Phase 2 | Neuroendocrine Tumor | Mar 2027 |
| Sinotau Pharmaceutical Group | Lutetium[177Lu] Oxodotreotide Injection Somatostatin receptor 2 (SSTR2)-targeting peptide receptor radionuclide therapy (PRRT) wit | SSTR2 | Phase 2 | Advanced Neuroendocrine Neoplasm | Jun 2027 |
| National Cancer Institute (NCI) | Lu-177-DOTATATE Somatostatin receptor 2 (SSTR2) targeting radiopharmaceutical; Lu-177 is a beta-emitting r | SSTR2 | Phase 2 | Pheochromocytoma; Gastroenteropancreatico Tumors | Jul 2027 |
| University of Alberta | 68Ga-HA-DOTATATE Somatostatin receptor (SSR) PET imaging tracer - gallium-68 labeled somatostatin analog | SSTR1, SSTR2, SSTR3, SSTR5 | Phase 2 | Neuroendocrine Tumors | Aug 2027 |
| Australasian Gastro-Intestinal Trials Group | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 2 | Neuroendocrine Tumors | Sep 2027 |
| University Hospital Heidelberg | Pasireotide Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist | SSTR5, SSTR2, SSTR1, SSTR3 | Phase 2 | Desmoplastic Small Round Cell Tumor | Oct 2027 |
| Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 68Ga-DOTATATE Somatostatin receptor 2 (SSTR2) agonist radiopharmaceutical | SSTR2 | Phase 2 | Neuroblastoma | Dec 2027 |
| Tata Memorial Hospital | Terbium 161 DOTATATE Auger-emitter peptide receptor radionuclide therapy targeting somatostatin receptors | SSTR2 | Phase 2 | Neuroendocrine Neoplasms (Tumours) | Feb 2028 |
| CSPC ZhongQi Pharmaceutical Technology | Octreotide Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 2 | Gastroenteropancreatic Neuroendocrine Tumors; Pancreas Head Cancer | Aug 2028 |
| Universitaire Ziekenhuizen KU Leuven | [18F]AlF-NOTA-octreotide Somatostatin receptor 2 (SSTR2) agonist PET tracer; octreotide labeled with fluorine-18 al | SSTR2 | Phase 2 | Stroke (CVA) or TIA | Sep 2029 |
| Orano Med | 212Pb-DOTAMTATE (AlphaMedix) Somatostatin receptor 2 (SSTR2)-targeting alpha-emitter therapy; radiolabeled octreotide a | SSTR2 | Phase 2 | Neuroendocrine Tumors | Dec 2030 |
| National Cancer Institute (NCI) | 68-Gallium DOTATATE somatostatin receptor 2 agonist for PET/CT imaging | SSTR2 | Phase 2 | VHL Pancreatic Neuroendocrine Tumors | Jan 2036 |
| RECORDATI GROUP | Pasireotide Diaspartate Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist | SSTR5, SSTR2, SSTR1, SSTR3 | Phase 2 | Post-Bariatric Hypoglycemia | – |
| Melanoma and Skin Cancer Trials Limited | Lutetium-177 (177Lu)-DOTATATE Peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptor 2 | SSTR2 | Phase 1 | Metastatic Merkel Cell Carcinoma | Dec 2026 |
| University Medical Center Groningen | [68Ga]Ga-DOTA-TOC Somatostatin receptor 2 (SSTR2) imaging agent | SSTR2 | Phase 1 | Nasopharyngeal Carcinoma (NPC) | Dec 2026 |
| University Hospital, Basel, Switzerland | 177Lu-DOTA-JR11 Radiolabeled somatostatin antagonist; 177Lu-emitting radiopharmaceutical targeting somatos | SSTR2, SSTR5 | Phase 1 | Meningioma | Dec 2026 |
| Joshua Palmer | Actinium Ac 225 DOTATATE RYZ101 Somatostatin receptor 2 (SSTR2) targeted alpha emitter; Ac-225 labeled somatostatin analog | SSTR2 | Phase 1 | Recurrent Meningioma | Dec 2026 |
| RayzeBio | RYZ401 Ac-225-based targeted alpha therapy for somatostatin receptor expression | SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 | Phase 1 | GEP-NET | Feb 2027 |
| Nanjing Chia-tai Tianqing Pharmaceutical | NTQ6179 somatostatin receptor subtype 2 (SSTR2) agonist | SSTR2 | Phase 1 | Acromegaly | Apr 2027 |
| Novartis | Lutetium Oxodotreotide Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 1 | Glioblastoma; Extensive Stage Small Cell Lung Cancer | May 2027 |
| National Health Research Institutes, Taiwan | Lanreotide Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist | SSTR5, SSTR2 | Phase 1 | Neuroendocrine Tumors,Gastroenteropancreatic | Aug 2027 |
| Jason Winnick | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 1 | Hypoglycemia; Iatrogenic | May 2028 |
| University Hospital, Basel, Switzerland | 61Cu-NODAGA-LM3 somatostatin receptor 2 (SSTR2) ligand labeled with copper-61 radioisotope for PET imaging | SSTR2 | Phase 1 | Neuroendocrine Tumors | Jun 2028 |
Neuroendocrine Tumors (17) Meningioma (3) Metastatic Pancreatic Neuroendocrine Tumor (3) Acromegaly (2) Gastroenteropancreatic Neuroendocrine Tumor (2) Neuroendocrine Neoplasm (2) Recurrent Meningioma (2) Gastro-enteropancreatic Neuroendocrine Tumor (2) GEP-NET (2) Gastroenteropancreatic Neuroendocrine Tumors (2) Somatostatin Receptor Positive (SSTR+) (1) Metastatic Neuroendocrine Prostate Cancer (1)
small molecule (19), protein or peptide (14), mixed (11), antibody (1)
Novartis (2) National Cancer Institute (NCI) (2) Sinotau Pharmaceutical Group (2) University Hospital, Basel, Switzerland (2) HTA (2) RayzeBio (2) Universitaire Ziekenhuizen KU Leuven (1) ITM Solucin (1) Nanjing Chia-tai Tianqing Pharmaceutical (1) Weill Medical College of Cornell University (1) University Hospital, Antwerp (1) University Hospital Heidelberg (1) Orano Med (1) Washington University School of Medicine (1) Antonio Fojo (1) Tata Memorial Hospital (1) Joshua Palmer (1) Camurus (1) Jason Winnick (1) Helsinki University Central Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.